10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

CDCA5 antibody - middle region

Rabbit Polyclonal Antibody
Catalog # AI14271

Product Information

Application	WB
Primary Accession	Q96FF9
Other Accession	NM_080668, NP_542399
Reactivity	Human
Predicted	Human
Host	Rabbit
Clonality	Polyclonal
Calculated MW	27601

Additional Information

Gene ID	113130
Alias Symbol	MGC16386, SORORIN
Other Names	Sororin, Cell division cycle-associated protein 5, p35, CDCA5
Format	Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose.
Reconstitution & Storage	Add 50 ul of distilled water. Final anti-CDCA5 antibody concentration is 1 mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at 20°C. Avoid repeat freeze-thaw cycles.
Precautions	CDCA5 antibody - middle region is for research use only and not for use in diagnostic or therapeutic procedures.


Protein Information

Name	CDCA5
Function	Regulator of sister chromatid cohesion in mitosis, stabilizing cohesin complex association with chromatin. May antagonize the action of WAPL which stimulates cohesin dissociation from chromatin. Cohesion ensures that chromosome partitioning is accurate in both meiotic and mitotic cells and plays an important role in DNA repair. Required for efficient DNA double-stranded break repair.
Cellular Location	Nucleus. Chromosome Cytoplasm. Note=Associates with nuclear chromatin from S phase until metaphase and is released in the cytoplasm upon nuclear envelope breakdown

References

Walker M.G.,et al.Curr. Cancer Drug Targets 1:73-83(2001).
Ota T.,et al.Nat. Genet. 36:40-45(2004).
Mural R.J.,et al.Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
Rankin S.,et al.Mol. Cell 18:185-200(2005).
Rankin S.,et al.Mol. Cell 18:609-609(2005).

Images



WB Suggested Anti-CDCA5 Antibody Titration: 0.2-1 µg/ml
ELISA Titer: 1:1562500
Positive Control: Human Placenta

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.